SOLIGENIX, INC. Deferred Tax Assets, Operating Loss Carryforwards
SOLIGENIX, INC. (SNGX) had Deferred Tax Assets, Operating Loss Carryforwards of $29.96 million as of 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Income Taxes › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Operating Loss Carryforwards, Components
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-31
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $29.96M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $28.44M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $27.52M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $27.25M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards |
|---|---|
| 2025-12-31 | $29.96M 10-K · filed 2026-03-31 |
| 2024-12-31 | $28.44M 10-K · filed 2026-03-31 |
| 2023-12-31 | $27.52M 10-K · filed 2025-03-21 |
| 2022-12-31 | $27.25M 10-K · filed 2024-03-15 |
| 2021-12-31 | $28.07M 10-K · filed 2023-03-31 |
| 2020-12-31 | $27.02M 10-K · filed 2022-03-29 |
| 2019-12-31 | $23.94M 10-K · filed 2021-03-30 |
| 2018-12-31 | $23.00M 10-K · filed 2020-03-30 |
| 2017-12-31 | $21.29M 10-K · filed 2019-03-26 |
| 2016-12-31 | $32.03M 10-K · filed 2018-03-15 |
| 2015-12-31 | $31.22M 10-K · filed 2017-03-27 |
| 2014-12-31 | $29.59M 10-K · filed 2016-03-24 |
| 2013-12-31 | $27.97M 10-K · filed 2015-03-25 |
| 2012-12-31 | $27.87M 10-K · filed 2014-03-26 |
| 2011-12-31 | $26.00M 10-K · filed 2013-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |